CB-839 (Telaglenastat)
Renal Cell Carcinoma
Key Facts
About Calithera Biosciences
Calithera Biosciences was founded in 2010 with a mission to develop novel small-molecule drugs targeting critical metabolic pathways in cancer cells and the tumor microenvironment. Its strategy centered on two core platforms: arginase inhibition to modulate immune function and glutaminase inhibition to starve tumors. The company advanced multiple candidates into clinical trials and built a pipeline of ~30 programs, but ultimately discontinued development and wound down operations in 2023 after a strategic review of its clinical prospects.
View full company profileAbout Calithera Biosciences
Calithera Biosciences was founded in 2010 with a mission to develop novel small-molecule drugs targeting critical metabolic pathways in cancer cells and the tumor microenvironment. Its strategy centered on two core platforms: arginase inhibition to modulate immune function and glutaminase inhibition to starve tumors. The company advanced multiple candidates into clinical trials and built a pipeline of ~30 programs, but ultimately discontinued development and wound down operations in 2023 after a strategic review of its clinical prospects.
View full company profileAbout Calithera Biosciences
Calithera Biosciences was founded in 2010 with a mission to develop novel small-molecule drugs targeting critical metabolic pathways in cancer cells and the tumor microenvironment. Its strategy centered on two core platforms: arginase inhibition to modulate immune function and glutaminase inhibition to starve tumors. The company advanced multiple candidates into clinical trials and built a pipeline of ~30 programs, but ultimately discontinued development and wound down operations in 2023 after a strategic review of its clinical prospects.
View full company profileTherapeutic Areas
Other Renal Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| XS008 (axitinib) | Xspray Pharma | Preclinical/Development |
| CDK7 allosteric inhibitor | Acellera | Pre-clinical |
| Precision Oncology - RCC | ReviveMed | Discovery |
| Ciforadenant (CPI-444) | Angel Pharmaceuticals | Phase 1b/2 |
| Lenvatinib (LENVIMA) | Eisai | Regulatory Review |
| Cabozantinib | Exelixis | Phase 3 |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| Casdatifan (AB521) | Arcus Biosciences | Phase 3 |
| XmAb®819 | Xencor | Phase 1 |
| MINC‑sunitinib | Suntec Medical | Preclinical |